
Languages Spoken: English
Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.
Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.
Clinical Locations
Rheumatology, Area E
801-581-7724
Fax: (801) 581-6069
Specialties
Board Certification and Academic Information
Academic Departments | Internal Medicine
-
Associate Professor Dermatology - Adjunct Associate Professor |
Academic Divisions | Rheumatology |
Board Certification | American Board of Internal Medicine (Sub: Rheumatology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5

Care provider's explanation of condition/problem
4.8/ 5

Care provider's effort to include me in decisions
4.8/ 5

Wait time at clinic
4.3/ 5

Care provider's concern for questions & worries
4.8/ 5

Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
September 10, 2022
UH HOSPITALS AND CLINICS
I had a much better experience with Dr Walsh, Dr Krutko, and their teams than another provider at UH rheumatology. I felt like I was a part of the decision making process. I felt that they had a genuine concern in accurately identifying what the issue was. Everything was explained clearly and concisely.
UofU Patient
September 10, 2022
UH HOSPITALS AND CLINICS
Taking this survey is useless!
UofU Patient
August 23, 2022
UH HOSPITALS AND CLINICS
Not sure. It was a tough travel for 2 70 year olds to travel four hours one way to be told wait until October, don't take your infusions and we will see what happens. So far I am not feeling good about my experience. If I don't hear anything back from the doctor soon about my scans and blood tests then our trip will be bad and probably not worth the travel from Idaho Falls to SLC.
UofU Patient
July 11, 2022
UH HOSPITALS AND CLINICS
Dr. Walsh is the best rheumatologist I've ever seen.
UofU Patient
June 27, 2022
UH HOSPITALS AND CLINICS
Dr. Walsh is very personable, and thorough. I have recommended her to others like she was recommended to me by a friend.
UofU Patient
May 25, 2022
UH HOSPITALS AND CLINICS
Dr Walsh and her fellow were both excellent-they listened and discussed everything with me.
UofU Patient
March 27, 2022
UH HOSPITALS AND CLINICS
We had to work together to go over my last appointment. I also had more health concerns outside of her field. She was very sympathetic and we were able to work out some questions I had. She was actually pretty amazing.
UofU Patient
February 15, 2022
UH HOSPITALS AND CLINICS
Dr. Walsh is one of the best things that has ever happened to me in the 30 years I have been suffering with PsA. She is knowledgeable and has made suggestions that have made my arthritis totally tolerable. I have been coming to Dr. Walsh since 2018 - I wish I had found her years ago! Where has she been all my life??
UofU Patient
January 24, 2022
UH HOSPITALS AND CLINICS
Dr Walsh listens carefully to me. She makes me feel like I'm part of the team and we are all working together yo improve my life. She is also a superb diagnostician.
UofU Patient
January 17, 2022
UH HOSPITALS AND CLINICS
Doctor was just a bit rushed it seemed. She did explain side effects and we did talk about going back to enbrel or starting a new one and we picked the new one, I felt more comfortable in her choice of that, due to her experience and history as a doctor specializing in my condition. Not a lot of eye contact but it was virtual and awkward for us both. She did ask me which way I would like to go with a medication. I just didn't have a lot of questions or more specific I was scared to ask them due to my social anxiety.
UofU Patient
November 27, 2021
UH HOSPITALS AND CLINICS
She is an excellent physician. She gives me great care.
UofU Patient
November 08, 2021
UH HOSPITALS AND CLINICS
Dr. Walsh always provides exemplary care
UofU Patient
November 07, 2021
UH HOSPITALS AND CLINICS
We had a lot of difficult crap to get through this day. It was extremely emotional. Dr Walsh was enormously empathetic
UofU Patient
October 16, 2021
UH HOSPITALS AND CLINICS
Dr. Walsh is excellent and is always attentive. She advises and listens. She remembers what you have discussed on previous visits. She is excellent.
UofU Patient
September 04, 2021
UH HOSPITALS AND CLINICS
Dr. Walsh sets the bar high for her kindness and interest in making me feel importsnt
UofU Patient
August 09, 2021
UH HOSPITALS AND CLINICS
As always - Dr Walsh is exemplary.
UofU Patient
July 25, 2021
UH HOSPITALS AND CLINICS
The doctor is very thorough. She seems to explore all treatment options. She changes my care to take advantage of all possible treatments.
UofU Patient
July 17, 2021
UH HOSPITALS AND CLINICS
I drive from Idaho to my appointments. Dr. Walsh and I had a very good conversation about by issues and discussed a plan to figure it out
UofU Patient
May 31, 2021
UH HOSPITALS AND CLINICS
Dr. Walsh defines the ideal physician. I am so fortunate to have had her as my rheumatologist since 2018. She sees the whole picture. She listens to my concerns, makes excellent care recommendations and my arthritic condition is so much better because of her direction. I have total faith in her.
UofU Patient
March 07, 2021
UH HOSPITALS AND CLINICS
excellent Doctor Who answered all questions.
UofU Patient
February 28, 2021
UH HOSPITALS AND CLINICS
Dr. Walsh is the best position in the industry, hands down. I am so lucky to have found her My health is improved, and actually my mind set has as well
Jessica Walsh, MD, is an Associate Professor at the University of Utah School of Medicine and George E. Wahlen Veteran Affairs Medical Center. As a Rheumatologist, her clinical interests include psoriatic diseases and spondyloarthritis. She developed and serves as the Director of the Spondyloarthritis Clinic. She is the Co-Director of the Combined Psoriatic Diseases Clinic in which psoriatic patients are jointly cared for by a rheumatologist and a dermatologist during the same clinic visit.
Walsh received her Medical Degree and Rheumatology training from the University of Utah. She is board certified in Internal Medicine and Rheumatology. She is currently a member and keynote speaker for the Spondyloarthritis Association of America and the National Psoriasis Foundation.
Academic Locations
Research Statement
Dr. Walsh’s research interests include psoriatic diseases and spondyloarthritis. She lead the development of the Program to Understand the Longterm Outcomes of Spondyloarthritis (PULSAR). She also founded and manages the Utah Psoriasis Initiative Arthritis (UPIA) registry that is designed to study the genetics and clinical outcomes of psoriatic diseases. She participates in clinical drug trials for spondyloarthritis and psoriatic arthritis patients.
Board Certification and Academic Information
Academic Departments | Internal Medicine
-
Associate Professor Dermatology - Adjunct Associate Professor |
Academic Divisions | Rheumatology |
Board Certification | American Board of Internal Medicine (Sub: Rheumatology) |
Education History
Graduate Training | University of Utah Clinical Investigation M.S.C.I, 2015 |
Fellowship | University of Utah School of Medicine Rheumatology Fellow, 2009 |
Chief Resident | University of Utah School of Medicine Internal Medicine Chief Resident, 2007 |
Residency | University of Utah School of Medicine Internal Medicine Resident, 2006 |
Internship | University of Utah School of Medicine Internal Medicine Intern, 2004 |
Professional Medical | University of Utah Medicine M.D., 2003 |
Graduate Training | Boise State University Business Administration M.B.A., 2003 |
Undergraduate | Whitman College Biology B.A., 1998 |
Selected Publications - Journal Articles
Journal Article
- Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L (2023). Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine, 105534.
- Pizzicato LN, Vadhariya A, Birt J, Ketkar AG, Bolce R, Grabner M, Pepe RS, Walsh JA (2022). Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm, 29, 1-12.
- Sen R, Kim E, Napier RJ, Cheng E, Fernandez A, Manning ES, Anderson ER, Maier KD, Hashim M, Kerr GS, Fang MA, Hou JK, Chang E, Walsh JA, Raychadhuri SP, Reimold A, Caplan L (2022). Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as biomarkers in axial spondyloarthritis: observational studies from the PULSAR registry. Arthritis Rheumatol, 75, 232-241.
- Gossec L, Walsh JA, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Chakravarty SD, Ogdie A (2022). Women with Psoriatic Arthritis Experience Higher Disease Burden than Men: Findings from a Real-World Survey in the USA and Europe. J Rheumatol.
- Gossec L, Walsh JA, Michaud K, Holdsworth E, Peterson S, Meakin S, Yang F, Booth N, Chakravarty SD, Piercy J, Dennis N, Ogdie A (2022). Impact of Fatigue on Health-Related Quality of Life and Work Productivity in Psoriatic Arthritis: Findings From a Real-World Survey. J Rheumatol, 49, 1221-1228.
- Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, Sandoval D, Lin CY, Walsh J (2021). Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open, 8(2).
- van der Horst-Bruinsma IE, de Vlam K, Walsh JA, Bolce R, Hunter T, Sandoval D, Zhu D, Geneus V, Soriano ER, Magrey M (2022). Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials. Adv Ther, 39(6), 2806-2819.
- Gavigan K, Nowell WB, Hunter T, Curtis JR, Malatestinic WN, Bolce RJ, Lisse JR, Walsh J (2022). Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. Rheumatol Ther, 9(2), 663-677.
- Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J (2022). Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry. Rheumatol Ther, 9(2), 735-751.
- Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Calderon DMS, Kiltz U (2022). Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care Res (Hoboken), 74(3), 451-460.
- Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119.
- Nowell WB, Gavigan K, Hunter T, Bolce RJ, Lisse JR, Himelein C, Dubey S, Curtis JR, Walsh JA (2021). Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. Rheumatol Ther, 9, 509-520.
- Walsh JA, Magrey M (2020). Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J Clin Rheumatol, 27(8), e547-e560.
- Orbai AM, Reddy SM, Dennis N, Villacorta R, Peterson S, Mesana L, Chakravarty SD, Lin I, Karyekar CS, Wang Y, Pacou M, Walsh J (2021). Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020. Clin Rheumatol, 40(12), 4933-4942.
- Nowell WB, Gavigan K, Hunter T, Malatestinic WN, Bolce RJ, Lisse JR, Himelein C, Curtis JR, Walsh JA (2021). Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. ACR Open Rheumatol, 4, 85-94.
- Bekele DI, Cheng E, Reimold A, Geier C, Ganuthula K, Walsh JA, Clegg DO, Dubreuil M, Kaushik P, Ng B, Chang E, Duong R, Park J, Kerr GS (2021). Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int, 42, 1925-1937.
- Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565.
- Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME (2021). The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol, 40(9), 3667-3677.
- Wan MT, Walsh JA, Craig ET, Husni ME, Scher JU, Reddy SM, Leung YY, Ogdie A (2020). A comparison of physical function instruments in psoriatic arthritis: HAQ-DI vs MDHAQ vs PROMIS10 global physical health. Rheumatology (Oxford), 60(5), 2307-2316.
- Walsh JA, Pei S, Penmetsa GK, Overbury RS, Clegg DO, Sauer BC (2020). Identifying Patients With Axial Spondyloarthritis in Large Datasets: Expanding Possibilities for Observational Research. J Rheumatol, 48(5), 685-692.
- Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD (2021). Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study. Adv Ther, 38(5), 2353-2364.
- Kiltz U, Wei JC, van der Heijde D, van den Bosch F, Walsh JA, Boonen A, Gensler LS, Hunter T, Carlier H, Dong Y, Li X, Bolce R, Strand V, Braun J (2020). Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. J Rheumatol, 48(2), 188-197.
- Magrey MN, Danve AS, Ermann J, Walsh JA (2020). Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc, 95(11), 2499-2508.
- Walsh JA, Magrey MN, Baraliakos X, Inui K, Weng MY, Lubrano E, van der Heijde D, Boonen A, Gensler LS, Strand V, Braun J, Hunter T, Li X, Zhu B, Len L, Marcelino Sandoval Calderon D, Kiltz U (2020). Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial. Arthritis Care Res (Hoboken), 74, 451-460.
- Walsh JA, Wan MT, Willinger C, Husni ME, Scher JU, Reddy SM, Ogdie A (2019). Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. J Rheumatol, 47(10), 1496-1505.
- Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD (2020). Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin, 36(7), 1245-1252.
- Overbury RS, Pei S, Breviu B, Clegg DO, Walsh JA (2020). Obstructive sleep apnea and fatigue in patients with inflammatory arthritis taking TNF-inhibitors. Int J Clin Rheumtol, 15(3), 38.
- Haberman R, Perez-Chada L, Siegel E, Reginato A, Webster D, Chandran V, Walsh JA Rosen C, Reddy S, Ogdie A, Scher J, Merola J (2020). Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2018 Annual Meeting Summary. J Psoriasis Psoriatic Arthritis.
- Dougados M, Wei JC, Landew R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups (2019). Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis, 79(2), 176-185.
- Walsh JA, Pei S, Penmetsa G, Hansen JL, Cannon GW, Clegg DO, Sauer BC (2019). Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods. J Rheumatol, 47(1), 42-49.
- Deodhar A, Gensler LS, Magrey M, Walsh JA, Winseck A, Grant D, Mease PJ (2019). Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap. Rheumatol Ther, 6(4), 487-501.
- Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228.
- Farahi JM, Lynn D, Anand P, Walsh JA, Hashim M, Duong R, Dellavalle RP, Reimold A, Kerr GS, Richards JS, Chang E, Kaushik P, Dubreuil M, Caplan L (2019). A Prospective Cross-Sectional Analysis of Construct Validity for the PALMPASS, A Brief Patient-Reported Outcome Measure for Psoriasis. J Psoriasis Psoriatic Arthritis, 4(4), 186-191.
- Walsh J, Hunter T, Schroeder K, Sandoval D, Bolce R (2019). Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006-2016. BMC Rheumatol, 3, 39.
- Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H (2019). Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther, 6(3), 435-450.
- Coit P, Kaushik P, Caplan L, Kerr G, Walsh JA, Dubreuil M, Reimold A, Sawalha A (2019). Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood. J Autoimmun, 102, 126-132.
- Walsh JA, Rozycki M, Yi E, Park Y (2019). Application of machine learning in the diagnosis of axial spondyloarthritis. Curr Opin Rheumatol, 31(4), 362-367.
- Braaten TJ, Zhang C, Presson AP, Breviu B, Clegg DO, Walsh JA (2019). Gender Differences in Psoriatic Arthritis with Fatigue, Pain, Function and Work Disability. J Psoriasis Psoriatic Arthritis, 4(4), 192-197.
- Walsh JA, Song X, Kim G, Park Y (3/24/2019). Counting the Costs of Ankylosing Spondylitis. 2517(106), 82-85.
- Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken), 71(1), 2-29.
- Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, Kwan-Morley J, Lin J, Marchetta P, Mease PJ, Merola JF, Miner J, Ritchlin CT, Siaton B, Smith BJ, Van Voorhees AS, Jonsson AH, Shah AA, Sullivan N, Turgunbaev M, Coates LC, Gottlieb A, Magrey M, Nowell WB, Orbai AM, Reddy SM, Scher JU, Siegel E, Siegel M, Walsh JA, Turner AS, Reston J (2018). Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol, 71(1), 5-32.
- Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ (2018). Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clin Rheumatol, 37(12), 3285-3296.
- Walsh JA, Song X, Kim G, Park Y (2018). Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database. Rheumatol Ther, 5(2), 463-474.
- Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. J Cardiol Cardiovasc Sci, 2(6), 17-23.
- Walsh JA, Jones H, Mallbris L, Duffin KC, Krueger GG, Clegg DO, Szumski A (2018). The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl), 8, 65-74.
- Walsh JA, Pei S, Penmetsa GK, Leng J, Cannon GW, Clegg DO, Sauer BC (2018). Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods. BMC Musculoskelet Disord, 19(1), 317.
- Walsh JA, Arledge T, Nurminen T, Peterson L, Stark J (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. J Rheumatol, 45(7), 922-928.
- Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol, 37(7), 1869-1878.
- Walsh JA, Song X, Kim G, Park Y (2018). Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Health Serv Res, 9(2), 115-121.
- Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gmez-Reino JJ, Aelion JA, ACTIVE investigators (2018). Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis, 77(5), 690-698.
- Walsh JA, Adejoro O, Chastek B, Park Y (2017). Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res, 7(4), 369-380.
- Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P (2018). Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a . J Manag Care Spec Pharm, 1-11.
- Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, Sauer BC (2017). Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol, 45(3), 430-436.
- Walsh JA, Tan H, Valdez H, Callis Duffin K (2017). Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity. J Psoriasis Psoriatic Arthritis, 2(4), 113-118.
- van der Heijde D, Dougados M, Landew R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A (2017). Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford), 56(9), 1498-1509.
- Walsh JA, Shao Y, Leng J, He T, Teng CC, Redd D, Treitler Zeng Q, Burningham Z, Clegg DO, Sauer BC (2017). Identifying Axial Spondyloarthritis in Electronic Medical Records of US Veterans. Arthritis Care Res (Hoboken), 69(9), 1414-1420.
- Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW (2016). Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ, 19(1), 34-43.
- Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K (2015). Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients. Br J Dermatol, 173(1), 272-4.
- Walsh JA, Zhou X, Clegg DO, Teng C, Cannon GW, Sauer B (2015). Mortality in American Veterans with the HLA-B27 gene. J Rheumatol, 42(4), 638-44.
- Sieper J, Landew R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP (2014). Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol, 67(3), 668-77.
- Kinard K, Walsh JA, Penmetsa GK, Warner JEA (2014). Adalimumab and non-arteritic anterior ischaemic optic neuropathy: A case report. Neuroophthalmology, 38(5), 272-277.
- Coates LC, Walsh J, Haroon M, FitzGerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS (2013). Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. Arthritis Care Res (Hoboken), 66(9), 1410-6.
- Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014). Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol, 41(8), 1670-4.
- Boehncke WH, Qureshi A, Merola JF, Thai D, Krueger GG, Walsh J, Kim N, Gottlieb AB (2013). Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol, 170(4), 772-86.
- Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, Gelfand JM, Krueger GG, Duffin KC (2013). Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol, 69(6), 931-7.
- Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2012). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis, 72(6), 986-91.
- Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93.
- Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999). Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol, 43(4), 269-76.
- Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar C, Booth N, Middleton-Dalby C, Chakravarty S, Kafka S, Dennis N, Gossec L (). The impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. (Epub ahead of print) Joint Bone Spine.
Conference Proceedings
Abstract
- Ogdie-Beatty A, Magrey M, Fitzsimmons R, Abdollahi S, Biljan A, Saffore C, Walsh JA (2021). Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study [Abstract]. 73(suppl 10).
- Penmetsa GK, Pei S, Sauer BC, Douglas K, Walker J, Clewell J, Feng B, Walsh JA (2021). Identifying Erosive Disease from Radiology Reports of Veterans with Inflammatory Arthritis with Natural Language Processing [Abstract]. 73(suppl 10).
- Sen R, Kim E, Cheng E, Ganuthula K, Fang M, Kerr G, Walsh JA, Chang E, Raychaudhuri S, Reimold A, Caplan L (2021). A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio [Abstract]. 73(suppl 10).
- Breviu B, Pei S, Kirkpatrick M, Feng B, Walsh JA (2021). Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety [Abstract]. 73(suppl 10).
- Braaten T, Pei s, Rathod A, Penmetsa G, Douglas K, Walker J, Clewell J, Walsh JA (2021). Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans [Abstract]. 73(suppl 10).